Who is sponsoring NCT04891263?

NCT04891263 is sponsored by Stanford University.

What drugs are being tested in NCT04891263?

Interventions in NCT04891263: Suture-Septoplasty, Surgical suture.

What condition does NCT04891263 study?

NCT04891263 studies Nasal Septum; Deviation, Congenital, Nasal Obstruction.

Is NCT04891263 still recruiting?

NCT04891263 is currently terminated. Last updated 3 April 2023.

Last reviewed 2023-04-03 · How we verify

NCT04891263

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Suture-based, Minimally Invasive Technique Used to Correct NSD

Terminated NA Last updated 3 April 2023

What this trial tests

NA trial testing Suture-Septoplasty in Nasal Septum; Deviation, Congenital in 4 participants. Terminated before completion.

Timeline

2 August 2021

Primary endpoint
13 September 2021

13 September 2021

Quick facts

Lead sponsor	Stanford University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	2 August 2021
Primary completion	13 September 2021
Estimated completion	13 September 2021
Sites	2 locations across United States

Drugs / interventions tested

Suture-Septoplasty
Surgical suture

Conditions studied

Nasal Septum; Deviation, Congenital — all drugs for Nasal Septum; Deviation, Congenital →
Nasal Obstruction — all drugs for Nasal Obstruction →

Sponsor

Stanford University

Who can join

18 and older, any sex, with Nasal Septum; Deviation, Congenital or Nasal Obstruction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nasal Septal Deviation (NSD) is one of the most common indications for surgery seen by ENT physicians, however, correction requires open surgery which is associated with several weeks of recovery. The purpose of this study is to elucidate whether a suture-based, minimally invasive technique can be used to safely and effectively address NSD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04891263 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 3 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04891263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing